Roivant launches new cell and gene therapy startup in Cincinnati

27 November 2018

Switzerland’s Roivant Sciences has launched a new biotech startup, in collaboration with the Cincinnati Children's Hospital Medical Center, called Aruvant Sciences.

The launch builds on an existing partnership dating back to early 2015. The new firm will work on innovative gene therapies for hematological conditions, starting with RVT-1801, an investigational gene therapy for sickle cell disease and β-thalassemia.

RVT-1801 utilizes proprietary technology intended to increase functioning red blood cells, and was developed at the Cincinnati Comprehensive Sickle Cell Center at Cincinnati Children's.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK